HIỆU QUẢ ĐIỀU TRỊ NỘI TIẾT KẾT HỢP TRASTUZUMAB TRÊN BỆNH NHÂN UNG THƯ VÚ TÁI PHÁT, DI CĂN THỤ THỂ NỘI TIẾT DƯƠNG TÍNH, HER2 DƯƠNG TÍNH TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the efficacy and safety of endocrine therapy combined with trastuzumab in patients with recurrent or metastatic HR+/HER2+ breast cancer. Methods: Descriptive retrospective–prospective study on 51 patients with recurrent/ metastatic HR+/HER2+ breast carcinoma treated at K Hospital between 01/2015 and 07/2025. Results: Mean age at diagnosis: 59.0. ORR 21.6%; stable disease 39.2%; CBR 60.8%. Median PFS: 6.5 months. No significant difference between AI vs. fulvestrant or with/without prior neoadjuvant chemotherapy (p > 0.05). Common adverse events: fatigue (9.8%), arthralgia (13.7%), bone pain (11.8%), cardiovascular AE (11.8%), mainly sinus tachycardia. Conclusion: Endocrine therapy plus trastuzumab confers significant clinical benefit with good tolerability, suggesting a feasible treatment option in HR+/HER2+ recurrent or metastatic breast cancer.